Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Coronavirus in Scotland: No new Covid-19 deaths for 19th day as 23 new cases confirmed
No new Covid-19 deaths for 19th day as 23 new cases confirmed
There have been no new deaths in Scotland overnight from Covid-19 for the nineteenth day in a row, as 23 new positive cases are announced today.
However, 15 of these new cases are in the NHS Grampian area.
First Minister Nicola Sturgeon announced that 270 patients are currently being treated for confirmed or suspected coronavirus in hospitals in Scotland - five more than yesterday.
and probably the very reason LifeArc and Dundee University selected SFX-01 from over 130 drug application candidates. ;-)
“There is evidence that Nrf2 activation can reduce the severity of acute lung injury and ARDS.
That's what I like about SFX-01's chances to treat Covid-19, although Professor Chalmers hypothesises its prevention potential, unlike many of the other drugs under evaluation, there's already documented and peer reviewed evidence that Nrf2 activation can reduce many of the severe lung conditions associated with Covid-19. Gla :-)
Covid-19 causes the development of slowly worsening lung damage called acute respiratory distress syndrome (ARDS) in around 10% of patients admitted to hospital.
When this occurs, no currently available drug can slow the progression of ARDS and patients ultimately require mechanical ventilation in intensive care until the inflammation resolves itself and the lungs begin to heal.
30% of patients with ARDS may go on to die, while the number of patients requiring ventilation for ARDS has been one of the major challenges for healthcare systems.
Finding treatments that can prevent the development of ARDS and improve patient recovery is therefore one of the top priorities for Covid-19 research.
James Chalmers, British Lung Foundation Professor of Respiratory Research at the University said: “SFX-01 is an anti-inflammatory medication that we believe may have the potential to reduce some of the worst outcomes of Covid-10.
“The body defends itself against inflammatory and oxidative stress by increasing levels of chemical called Nrf2.
“SFX-01 activates the Nrf2 system and puts it into overdrive to enhance defences against inflammatory damage.
“There is evidence that Nrf2 activation can reduce the severity of acute lung injury and ARDS.
“As such, we hypothesise that early treatment with an Nrf2 activator in patients hospitalised with COVID-19 may prevent deterioration and help to preserve precious ICU resources in the context of the pandemic.
Courtesy of Oranolio on advfn...Gla ;-)
From Evgen, I emailed them again about the covid-19 trial and again they responded very promptly....
The trial is being run by the University of Dundee. The study was expected to begin enrolment last month, in July.
Could've started on the 1st July.
19 days in a row!!! ;-)
Scottish numbers: 4 August 2020
23 new confirmed cases of COVID-19; this is 0.9% of newly tested individuals.
0 new reported death(s) of people who have tested positive.
4 people were in intensive care last night with confirmed COVID-19.
270 people were in hospital with confirmed COVID-19.
5,879 new tests for COVID-19 that reported results.
Highlights
The host inflammatory response is a crucial determinant of disease outcome and correlates with disease severity in SARS-CoV-2-induced infection, for which there is no treatment to date.
Activation of transcription factor nuclear factor erythroid 2 p45-related factor 2 (NRF2) promotes resolution of inflammation and, in parallel, restores cellular redox and protein homeostasis, and facilitates tissue repair.
NRF2 can be activated by pharmacological inducers that target Kelch-like ECH-associated protein 1 (KEAP1), the principal negative regulator of NRF2.
The available information on pharmacokinetics, pharmacodynamics, safety, and efficacy for the NRF2 activators sulforaphane and bardoxolone methyl (currently in advanced clinical trials for other disease indications) in humans makes them excellent candidates for testing in randomized clinical trials in COVID-19.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(20)30165-6?sf236269648=1
A.T.D-K. is a member of the Scientific Advisory Board of Evgen Pharma and a consultant for Aclipse Therapeutics and Vividion Therapeutics.
20 May 2020
News
Roche enters $135m drug discovery deal with Vividion Therapeutics
https://www.pharmaceutical-technology.com/news/roche-vividion-therapeutics-deal/
Published June 2020
KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease
Abstract
Redox imbalance and persistent inflammation are the underlying causes of most chronic diseases. Mammalian cells have evolved elaborate mechanisms for restoring redox homeostasis and resolving acute inflammatory responses. One prominent mechanism is that of inducing the expression of antioxidant, anti-inflammatory and other cytoprotective proteins, while also suppressing the production of pro-inflammatory mediators, through the activation of transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2). At homeostatic conditions, NRF2 is a short-lived protein, which avidly binds to Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 functions as (i) a substrate adaptor for a Cullin 3 (CUL3)-based E3 ubiquitin ligase that targets NRF2 for ubiquitination and proteasomal degradation, and (ii) a cysteine-based sensor for a myriad of physiological and pharmacological NRF2 activators. Here, we review the intricate molecular mechanisms by which KEAP1 senses electrophiles and oxidants. Chemical modification of specific cysteine sensors of KEAP1 results in loss of NRF2-repressor function and alterations in the expression of NRF2-target genes that encode large networks of diverse proteins, which collectively restore redox balance and resolve inflammation, thus ensuring a comprehensive cytoprotection. We focus on the cyclic cyanoenones, the most potent NRF2 activators, some of which are currently in clinical trials for various pathologies characterized by redox imbalance and inflammation.
Keywords: KEAP1; NRF2; anti-inflammatory; antioxidant; cysteine; redox.
Conflict of interest statement
A.T.D-K. is a member of the Scientific Advisory Board of Evgen Pharma and a consultant for Aclipse Therapeutics and Vividion Therapeutics.
https://pubmed.ncbi.nlm.nih.gov/32574549/